Johnson & Johnson Vision Announces the US Launch of the Tecnis Multifocal Toric II IOL

Source: Johnson & Johnson Vision

Johnson & Johnson Vision announced the US launch of the Tecnis Multifocal Toric II IOL, the first multifocal IOL approved on the new Tecnis Toric II platform. The square-edge Tecnis Multifocal Toric II implant features a new generation of frosted haptics, offering more surface texture and friction between the lens haptics and the capsular bag. The new IOLs will be commercially available in May, initially launching in cylinder powers of 1.50, 2.25, 3.00 and 3.75 on the 3.25 D and 2.75 D multifocal add power designs.

“Cataract patients expect clear vision after cataract surgery with both their presbyopia and astigmatism corrected. I am delighted to have a Toric II version of the Tecnis Multifocal available for use in the U.S. It’s always been my belief that the true strength of the Tecnis Multifocal platform has always been high-quality distance visual acuity and near vision at a customizable range. In my experience, no other IOL platform offers these attributes,” Steven Dell, MD, Medical Director, Dell Laser Consultants, said in a company news release. “The ability to simultaneously address presbyopia and astigmatism and implant a lens with a new frosted haptic design that holds in the proper position, is a welcome addition.”

Forty-seven percent of cataract patients selecting a presbyopia-correcting technology also have clinically relevant astigmatism of >1.00 D, according to J&J Vision. Even this small amount of astigmatism can cause troublesome blurring without correction during cataract surgery. Toric IOLs have been shown to be more predictable for correction when compared to manual methods, but questions over rotational stability have historically been a hurdle to more widespread adoption.

“With Tecnis Multifocal Toric II IOLs, Johnson & Johnson Vision is delivering a more reliable solution for doctors to address rotational stability when treating today’s cataract patient,”said Rajesh K. Rajpal, MD, Chief Medical Officer and Global Head of Clinical and Medical Affairs, Johnson & Johnson Vision. “As an industry leader, we are continuing to innovate complete presbyopia-correcting solutions for our customers and patients and working to take astigmatism patient care to the next level.”

Two post-market clinical trials are currently underway to determine the rotational stability and visual outcomes associated with the new Tecnis Toric II platform. These trials are collecting qualitative and quantitative performance measures at various sites across U.S.


Related Content